Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the effect of steady-state concentrations of lazertinib on the single-dose pharmacokinetics (PK) of probe substrates (midazolam, rosuvastatin, and metformin) in healthy adult participants.
Interventions
DRUGLazertinib
Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
DRUGMidazolam
Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
DRUGRosuvastatin
Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
DRUGMetformin
Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy on the basis of medical history at screening only, and physical examination, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and at admission to the study center * Healthy on the basis of clinical laboratory tests performed at screening and at admission to the study center. * A woman who is considered surgically sterile but not postmenopausal, must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hCG\]) at screening and a negative urine pregnancy test on Study Day 1. (exemptions: pregnancy test not required in female participants with prior hysterectomy or prior bilateral oophorectomy) * Male participants must agree to use an adequate contraception method as deemed appropriate by the investigator * Non-smoker or not using tobacco containing products for at least 6 months before first study drug administration and test negative for cotinine at screening and Study Day 1
Exclusion criteria
* History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, that in the opinion of the investigator, with written concurrence with the sponsor's medical monitor is considered cured with minimal risk of recurrence) * History of suspected or confirmed coronavirus disease 2019 within 4 weeks before intake of study drug, or tests positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at admission to the study site * Known allergies, hypersensitivity, or intolerance to lazertinib or its excipients or probe substrates * Taken any disallowed therapies, concomitant therapy before the planned first dose of study drug * Had major surgery, (example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 4 weeks after the last dose of study drug administration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration of Probe Substrates (Midazolam, Rosuvastatin, and Metformin) Co-administered with Lazertinib (Day 13) as Test Versus Plasma Concentration of Probe Substrates Administered Alone (Day 1) as Reference | Predose up to 12 hours postdose (Days 1 and 13) | Plasma samples will be analyzed to determine concentrations of midazolam and its metabolite 1-OH-midazolam, rosuvastatin, metformin, or lazertinib using a validated, specific, and sensitive method on Day 1 versus Day 13 as a part of drug-drug interaction (DDI) assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with AEs by Severity | Up to 56 days | Number of participants with AEs by severity will be reported. AE severity is a clinical determination of the intensity of an AE and is assessed by using the standard grades as follows: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to AE. |
| Number of Participants with Clinically Significant Changes in Laboratory Test Results | Up to 28 days | Number of participants with change in clinical laboratory test results (including hematology and serum chemistry) will be reported. |
| Number of Participants with Clinically Significant Abnormalities in 12-lead Electrocardiograms (ECGs) | Up to 28 days | Number of participants with clinically significant abnormalities in ECGs will be reported. |
| Number of Participants with Adverse Events (AEs) | Up to 56 days | AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
| Number of Participants with Clinically Significant Abnormalities in Physical Examination | Up to 28 days | Number of participants with clinically significant abnormalities in physical examination (including height and body weight) will be reported. |
| Plasma Concentrations of Lazertinib at steady-state | Predose on Day 7, 9, 11, 13, and 14 | Plasma concentration of lazertinib at steady-state will be assessed. |
| Plasma Concentrations of Lazertinib Following Repeat Dosing for 10 Days | Day 14, 15, 16, 17, 21, and 28 | Plasma concentration of lazertinib following repeat dosing for 10 days will be assessed. |
| Number of Participants with Clinically Significant Abnormalities in Vital Signs | Up to 28 days | Number of participants with clinically significant abnormalities in vital signs (including temperature \[oral\], pulse rate, and blood pressure) will be reported. |
Countries
United States
Outcome results
None listed